Showing results (41-50 of 62) with videos related to
Sort By:
Pageof 7
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.Scientific Reports|August 18, 2022
STUB1 is an intracellular checkpoint for interferon gamma sensingSimon Ng, Shuhui Lim, Adrian Chong Nyi Sim, et al.Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.Nature Medicine|August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.Neuro-Oncology|October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.Nature Medicine|July 18, 2018
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerSeung Tae Kim, Razvan Cristescu, Adam J Bass, et al.Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.Pageof 7